Last reviewed · How we verify
Marcaine 0.25% infiltration
At a glance
| Generic name | Marcaine 0.25% infiltration |
|---|---|
| Also known as | Marcaine |
| Sponsor | Innocoll |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Erector Spinae Block Vs Ketamine-based Multimodal Analgesia Protocol in Lumber Decompressive Surgery (NA)
- Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block (NA)
- Postoperative Analgesia and Ventilation After Cardiac Surgery
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- Evaluation of Pain Management After Surgery When Using Exparel in the Pediatric Population (PHASE2)
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Hemorrhoid Surgery (NA)
- Ultrasound Guided Quadratus Lumborum Block, Thoracolumbar Interfascial Plane Block, and Local Anesthetic Infiltration for Lumbar Spine Fixation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Marcaine 0.25% infiltration CI brief — competitive landscape report
- Marcaine 0.25% infiltration updates RSS · CI watch RSS
- Innocoll portfolio CI